トラマドール医薬品の2030年までの市場予測：タイプ、剤形、流通チャネル、地域別の世界分析

Stratistics MRCによると、世界のトラマドール医薬品市場は2023年に49億米ドルを占め、予測期間中にCAGR 8.8％で成長し、2030年には88億4,000万米ドルに達すると予測されています。

痛みの治療に使用される人工オピオイド鎮痛薬はトラマドールと呼ばれます。中等度から重度の痛みの治療によく推奨されています。従来のオピオイドとは対照的に、トラマドールはmu-オピオイド受容体への結合に加え、セロトニンとノルエピネフリンの再取り込みを阻害することで機能します。さらに、他のオピオイドと比較すると、この二重作用により、呼吸抑制のリスクが低くなると同時に、薬物の鎮痛効果にも寄与すると考えられます。

米国疾病予防管理センター（CDC）によると、米国の成人では約5,850万人が医師から関節炎と診断されており、2040年には7,840万人が医師から関節炎と診断されると推定されています。

疼痛管理に関する知識の増加

一般市民やヘルスケア専門家の疼痛管理に対する意識は高まっており、その結果、安全で効率的な疼痛緩和方法に注目が集まっています。トラマドールは、疼痛治療における成功の歴史が確立されており、この発展から利益を得ています。さらに、カスタマイズされた治療レジメンの継続的なニーズと、疼痛管理のための様々な代替手段に対する意識の高まりが、医薬品業界におけるトラマドールの売上を促進する要因となっています。

耐性と副作用の発現

トラマドールの普及を阻む障害のひとつに、吐き気、めまい、便秘などの副作用の発生があります。さらに、繰り返し使用することで耐性が生じ、効果を維持するために用量を変更しなければならなくなることもあります。ヘルスケア担当者は、鎮痛の必要性と副作用および耐性の抑制とを慎重に比較検討しなければならないです。この判断は、トラマドールの一般的な受容性と長期使用に影響します。

製剤化への革新的アプローチ

現在進行中のトラマドール医薬品の開発にはチャンスがあります。薬の有効性と患者のコンプライアンスは、併用療法や徐放性製剤など、最先端の送達方法に集中した研究開発イニシアチブによって改善することができます。さらに、トラマドールは、投与頻度、副作用、全体的な治療結果などの問題に対処する改良された製剤により、より洗練され適応性のある疼痛管理ソリューションとして位置づけられる可能性があります。

疼痛管理代替療法の競合

疼痛管理市場は常に変化しており、絶え間ない研究の結果、新たな治療法が開発されています。トラマドールの市場シェアは、非オピオイド鎮痛薬、医療機器、非薬理学的介入との競合によるリスクにさらされています。さらに、有効性、安全性、患者の嗜好の面でも、トラマドールは医療提供者が検討している他の疼痛管理選択肢との競争に直面しています。

COVID-19の影響

トラマドール医薬品市場は、COVID-19の大流行からさまざまな影響を受けています。ヘルスケアと医薬品への注目の高まりにより、疼痛管理ソリューションに対する需要は増加しているが、世界サプライチェーンの混乱、ヘルスケアの優先順位の変化、パンデミック関連問題へのリソースの振り向けなどにより、市場力学も影響を受けています。さらに、ヘルスケアサービスの閉鎖や制限も患者の医療アクセスに影響を及ぼしており、トラマドールの一般的な消費量や処方慣行にも影響を及ぼしている可能性があります。

予測期間中、錠剤セグメントが最大となる見込み

トラマドール医薬品市場では、錠剤セグメントが最大のシェアを占めると予想されます。安定性、携帯性、使用の簡便性から、錠剤が好まれます。保存期間が長く、正確な投与が可能で、患者にやさしいことから、錠剤が強く推奨されています。多くの治療クラスにおいて、錠剤は便利で好まれ、患者の服薬アドヒアランスを高める形態となっています。さらに、製薬業界で最大の市場シェアを獲得しているのは錠剤であり、その理由は一貫した製造プロセス、堅固で携帯しやすい性質、患者や医療従事者の間での人気などです。

予測期間中、オンライン薬局セグメントが最も高いCAGRが見込まれる

トラマドール医薬品市場の中では、オンライン薬局分野が最も急速に成長しています。オンライン薬局の急速な拡大は、デジタルプラットフォームの利用拡大、電子商取引の進歩、顧客に提供する使いやすさに起因しています。さらに、人々は自宅にいながらオンラインで薬を注文・入手できるため、実店舗の薬局を訪れる手間が省ける。

最大のシェアを占める地域：

欧州地域が最大のシェアを占めると予測されています。強固なヘルスケアシステム、高度なイノベーション、充実した患者基盤が欧州医薬品市場を定義しています。この地域の医薬品市場シェアは、ドイツ、フランス、英国などの欧州連合（EU）諸国の影響を大きく受けています。さらに、欧州は大手製薬会社、強力な規制環境、継続的な医学研究の進歩により、医薬品の世界ではよく知られています。

CAGRが最も高い地域：

アジア太平洋地域のCAGRが最も高いです。ヘルスケアインフラの成長、可処分所得の増加、医薬品の研究開発活動の拡大、高齢化と人口増加などの要因により、アジア太平洋地域の医薬品産業は急速に拡大しています。さらに、医薬品製造、イノベーション、ヘルスケアへのアクセスに重点を置く中国やインドなどの新興国は、この成長に不可欠な存在です。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のトラマドール医薬品市場：タイプ別

• オーラルタイプ
• インジェクションタイプ
• その他のタイプ

第6章 世界のトラマドール医薬品市場：剤形別

• タブレット
• カプセル
• 液体
• その他の剤形

第7章 世界のトラマドール医薬品市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル

第8章 世界のトラマドール医薬品市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• CSL Limited
• Hexal AG
• Labopharm
• Amneal Pharmaceuticals
• Mankind Pharma Ltd
• Par Pharmaceuticals
• Grunenthal Group
• Nippon Shinyaku Co., Ltd.
• Kosher Pharmaceuticals
• Mundipharma
• Atoz Pharmaceuticals
• Rompharm Company
• Nippon Shinyaku

List of Tables

• Table 1 Global Tramadol Drug Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Tramadol Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Tramadol Drug Market Outlook, By Oral Type (2021-2030) ($MN)
• Table 4 Global Tramadol Drug Market Outlook, By Injection Type (2021-2030) ($MN)
• Table 5 Global Tramadol Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 6 Global Tramadol Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 7 Global Tramadol Drug Market Outlook, By Tablet (2021-2030) ($MN)
• Table 8 Global Tramadol Drug Market Outlook, By Capsule (2021-2030) ($MN)
• Table 9 Global Tramadol Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 10 Global Tramadol Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 11 Global Tramadol Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 12 Global Tramadol Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 13 Global Tramadol Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 14 Global Tramadol Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 15 Global Tramadol Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 16 North America Tramadol Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 17 North America Tramadol Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 18 North America Tramadol Drug Market Outlook, By Oral Type (2021-2030) ($MN)
• Table 19 North America Tramadol Drug Market Outlook, By Injection Type (2021-2030) ($MN)
• Table 20 North America Tramadol Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 21 North America Tramadol Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 22 North America Tramadol Drug Market Outlook, By Tablet (2021-2030) ($MN)
• Table 23 North America Tramadol Drug Market Outlook, By Capsule (2021-2030) ($MN)
• Table 24 North America Tramadol Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 25 North America Tramadol Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 26 North America Tramadol Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 27 North America Tramadol Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 28 North America Tramadol Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 29 North America Tramadol Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 30 North America Tramadol Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 31 Europe Tramadol Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 32 Europe Tramadol Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 33 Europe Tramadol Drug Market Outlook, By Oral Type (2021-2030) ($MN)
• Table 34 Europe Tramadol Drug Market Outlook, By Injection Type (2021-2030) ($MN)
• Table 35 Europe Tramadol Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 36 Europe Tramadol Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 37 Europe Tramadol Drug Market Outlook, By Tablet (2021-2030) ($MN)
• Table 38 Europe Tramadol Drug Market Outlook, By Capsule (2021-2030) ($MN)
• Table 39 Europe Tramadol Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 40 Europe Tramadol Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 41 Europe Tramadol Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 42 Europe Tramadol Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 43 Europe Tramadol Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 44 Europe Tramadol Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 45 Europe Tramadol Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 46 Asia Pacific Tramadol Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 47 Asia Pacific Tramadol Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 48 Asia Pacific Tramadol Drug Market Outlook, By Oral Type (2021-2030) ($MN)
• Table 49 Asia Pacific Tramadol Drug Market Outlook, By Injection Type (2021-2030) ($MN)
• Table 50 Asia Pacific Tramadol Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 51 Asia Pacific Tramadol Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 52 Asia Pacific Tramadol Drug Market Outlook, By Tablet (2021-2030) ($MN)
• Table 53 Asia Pacific Tramadol Drug Market Outlook, By Capsule (2021-2030) ($MN)
• Table 54 Asia Pacific Tramadol Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 55 Asia Pacific Tramadol Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 56 Asia Pacific Tramadol Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 57 Asia Pacific Tramadol Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 58 Asia Pacific Tramadol Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 59 Asia Pacific Tramadol Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 60 Asia Pacific Tramadol Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 61 South America Tramadol Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 62 South America Tramadol Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 63 South America Tramadol Drug Market Outlook, By Oral Type (2021-2030) ($MN)
• Table 64 South America Tramadol Drug Market Outlook, By Injection Type (2021-2030) ($MN)
• Table 65 South America Tramadol Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 66 South America Tramadol Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 67 South America Tramadol Drug Market Outlook, By Tablet (2021-2030) ($MN)
• Table 68 South America Tramadol Drug Market Outlook, By Capsule (2021-2030) ($MN)
• Table 69 South America Tramadol Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 70 South America Tramadol Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 71 South America Tramadol Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 72 South America Tramadol Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 73 South America Tramadol Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 74 South America Tramadol Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 75 South America Tramadol Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 76 Middle East & Africa Tramadol Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 77 Middle East & Africa Tramadol Drug Market Outlook, By Type (2021-2030) ($MN)
• Table 78 Middle East & Africa Tramadol Drug Market Outlook, By Oral Type (2021-2030) ($MN)
• Table 79 Middle East & Africa Tramadol Drug Market Outlook, By Injection Type (2021-2030) ($MN)
• Table 80 Middle East & Africa Tramadol Drug Market Outlook, By Other Types (2021-2030) ($MN)
• Table 81 Middle East & Africa Tramadol Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 82 Middle East & Africa Tramadol Drug Market Outlook, By Tablet (2021-2030) ($MN)
• Table 83 Middle East & Africa Tramadol Drug Market Outlook, By Capsule (2021-2030) ($MN)
• Table 84 Middle East & Africa Tramadol Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 85 Middle East & Africa Tramadol Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 86 Middle East & Africa Tramadol Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 87 Middle East & Africa Tramadol Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 88 Middle East & Africa Tramadol Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 89 Middle East & Africa Tramadol Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 90 Middle East & Africa Tramadol Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

According to Stratistics MRC, the Global Tramadol Drug Market is accounted for $4.90 billion in 2023 and is expected to reach $8.84 billion by 2030 growing at a CAGR of 8.8% during the forecast period. An artificial opioid analgesic used to treat pain is called tramadol. It is frequently recommended for the treatment of moderate-to-severe pain. In contrast to conventional opioids, tramadol functions by inhibiting the reuptake of serotonin and norepinephrine in addition to binding to mu-opioid receptors. Moreover, when compared to other opioids, this dual action may provide a lower risk of respiratory depression while also contributing to the drug's analgesic effects.

According to Centers for Disease Control and Prevention (CDC), in the U.S. adults, about 58.5 million people had doctor-diagnosed arthritis and by 2040, an estimated 78.4 million adults will have doctor-diagnosed arthritis.

Market Dynamics:

Driver:

Increasing knowledge about pain management

The general public and healthcare professionals are becoming more aware of pain management, and this has led to a growing focus on safe and efficient pain relief methods. With its well-established history of success in the treatment of pain, tramadol gains from this development. Additionally, the ongoing need for customized treatment regimens and growing awareness of various alternatives for managing pain are factors driving tramadol's sales in the pharmaceutical industry.

Restraint:

Development of tolerance and adverse effects

One obstacle to Tramadol's widespread use is the occurrence of side effects, which include nausea, dizziness, and constipation. Furthermore, repeated use may cause tolerance, which calls for dose changes to maintain effectiveness. Healthcare practitioners must carefully weigh the need for pain relief against the control of side effects and tolerance. This decision will affect the general acceptability and long-term use of tramadol.

Opportunity:

Innovative approaches to medicine formulation

There are opportunities in the ongoing development of tramadol formulations. The effectiveness of the medication and patient compliance can be improved by research and development initiatives that concentrate on cutting-edge delivery methods, such as combination therapies or extended-release formulations. Moreover, tramadol may be positioned as a more sophisticated and adaptable pain management solution with improved formulations that address problems like dose frequency, adverse effects, and overall therapeutic outcomes.

Threat:

Alternative pain management therapies competition

The market for pain management is always changing, and new treatments are being developed as a result of continuous research. Tramadol's market share is at risk from competition from non-opioid analgesics, medical devices, and non-pharmacological interventions. Additionally, in terms of effectiveness, safety, and patient preferences, tramadol is facing competition from other pain management options that healthcare providers are investigating.

COVID-19 Impact:

The Tramadol medication market has experienced a variety of effects from the COVID-19 pandemic. The demand for pain management solutions has increased due to the increased focus on healthcare and pharmaceuticals; however, market dynamics have also been affected by disruptions in the global supply chain, changes in healthcare priorities, and the redirection of resources towards pandemic-related issues. Furthermore, lockdowns and limitations on healthcare services have also impacted patient access to care, which may have an impact on the general amount of tramadol consumed as well as prescribing practices.

The Tablet segment is expected to be the largest during the forecast period

In the tramadol drug market, the tablet segment is expected to account for the largest share. Because of their stability, portability, and simplicity of use, tablets are preferred. The extended shelf life, accurate dosage delivery, and patient-friendly qualities of these medications make them highly recommended. In many therapeutic classes, tablets provide a convenient and preferred form that is highly conducive to patient adherence to medication. Moreover, the pharmaceutical industry's largest market share is attained by tablets because of their consistent manufacturing processes, solid and portable nature, and popularity among patients and healthcare providers.

The Online Pharmacy segment is expected to have the highest CAGR during the forecast period

Within the Tramadol drug market, the online pharmacy segment is growing at the fastest rate. The swift expansion of online pharmacies can be attributed to the growing utilization of digital platforms, advancements in electronic commerce, and the ease of use they provide to customers. Additionally, people can order and obtain medications online from the convenience of their homes, saving them the trouble of physically visiting brick-and-mortar pharmacies.

Region with largest share:

European region is projected to hold the largest share. The robust healthcare system, elevated innovation, and substantial patient base define the European pharmaceutical market. The pharmaceutical market share of the area is largely influenced by European Union nations like Germany, France, and the United Kingdom. Moreover, Europe is well-known in the world of pharmaceuticals because of its large pharmaceutical companies, strong regulatory environments, and continuous medical research advancements.

Region with highest CAGR:

Asia-Pacific region is growing at the highest CAGR. Due to factors like growing healthcare infrastructure, rising disposable incomes, expanding pharmaceutical research and development activities, and an aging and sizable population, the pharmaceutical industry in Asia-Pacific is expanding rapidly. Furthermore, with an emphasis on pharmaceutical manufacturing, innovation, and healthcare accessibility, emerging economies like China and India are essential to this growth.

Key players in the market:

Some of the key players in Tramadol Drug market include CSL Limited, Hexal AG, Labopharm, Amneal Pharmaceuticals, Mankind Pharma Ltd, Par Pharmaceuticals, Grunenthal Group, Nippon Shinyaku Co., Ltd., Kosher Pharmaceuticals, Mundipharma, Atoz Pharmaceuticals, Rompharm Company and Nippon Shinyaku.

Key Developments:

In December 2023, Amneal Pharmaceuticals, Inc. and BIAL - Portela & Ca., S.A., today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® in the U.S. starting on December 18, 2023. Amneal expects to begin distribution of ONGENTYS® in early 2024.

In August 2023, Grunenthal GmbH and Kyowa Kirin Co have announced the successful completion of a deal to enter into a joint venture collaboration for Kyowa Kirin International's established medicines portfolio.The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis.

In November 2022, CSL Limited has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings to access its late stage, next-generation self-amplifying mRNA (sa-mRNA) vaccine tech: prepared to spend more than $4bn on the deal to accelerate its mRNA journey.

Types Covered:

• Oral Type
• Injection Type
• Other Types

Dosage Forms Covered:

• Tablet
• Capsule
• Liquid
• Other Dosage Forms

Distribution Channels Covered:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Tramadol Drug Market, By Type

• 5.1 Introduction
• 5.2 Oral Type
• 5.3 Injection Type
• 5.4 Other Types

6 Global Tramadol Drug Market, By Dosage Form

• 6.1 Introduction
• 6.2 Tablet
• 6.3 Capsule
• 6.4 Liquid
• 6.5 Other Dosage Forms

7 Global Tramadol Drug Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacy
• 7.3 Retail Pharmacy
• 7.4 Online Pharmacy
• 7.5 Other Distribution Channels

8 Global Tramadol Drug Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 CSL Limited
• 10.2 Hexal AG
• 10.3 Labopharm
• 10.4 Amneal Pharmaceuticals
• 10.5 Mankind Pharma Ltd
• 10.6 Par Pharmaceuticals
• 10.7 Grunenthal Group
• 10.8 Nippon Shinyaku Co., Ltd.
• 10.9 Kosher Pharmaceuticals
• 10.10 Mundipharma
• 10.11 Atoz Pharmaceuticals
• 10.12 Rompharm Company
• 10.13 Nippon Shinyaku